Showing 1621-1630 of 2050 results for "".
- Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopiahttps://modernod.com/news/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/2482295/Dopavision announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children. The 6-month outcomes of the randomized, controlled tria
- Haag-Streit Launches 3D Imaging Option for the Imaging Module 910https://modernod.com/news/haag-streit-launches-3d-imaging-option-for-the-imaging-module-910/2482281/Haag-Streit announced the launch of the Imaging Module 910 3D. "To-date, ophthalmologists have been able to document slit lamp images, but only in 2D. The images presented in two dimensions lack depth, which limits the comprehensive visualization of the observed content. By enhanci
- Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/Bausch + Lomb announced the US launch of Zenlens Echo, a non-prosthetic, custom scleral contact lens. The Echo is designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative con
- Ora Inc. and Singapore Eye Research Institute Announce Partnershiphttps://modernod.com/news/ora-and-singapore-eye-research-institute-unveil-partnership-to-propel-ophthalmology-innovation-globally/2482264/Contract Research Organization (CRO) Ora Inc. announced a partnership with the Singapore Eye Research Institute (SERI) that aims to provide early-stage innovators with comprehensive research support. Financial terms of the deal were not disclosed.
- Qlaris Bio Completes $24 Million Series B Financing Round to Advance IOP-lowering Drug Candidate for Glaucomahttps://modernod.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/Qlaris Bio announced it has closed a $24 million Series B financing round to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure (EVP). Qlaris is currently conducting two US ph
- Ocular Therapeutix Releases Topline Results for Phase 1 Trial of Axpaxli for Diabetic Retinopathyhttps://modernod.com/news/ocular-therapeutix-axpaxli-in-diabetic-retinopathy-evaluated-in-phase-1-helios-clinical-trial/2482237/Ocular Therapeutix announced positive topline results from the phase 1 HELIOS study, which is evaluating the safety, tolerability, and efficacy of drug candidate Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without di
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- Nidek Announces Winners of the 4th Annual Image of the Year Awardhttps://modernod.com/news/nidek-announces-winners-of-the-4th-annual-image-of-the-year-award/2482217/Nidek has announced the winners of the 4th annual 'Image of the Year' Award. With the contest theme, "invisible to visible," this year featured diabetic retinopathy (DR) cases which often require examination of the fovea to the extreme periphery. Eye care pr
- Wearing Glasses Boosts Income by a Third in Low-Income Communities, Finds Landmark New Studyhttps://modernod.com/news/wearing-glasses-boosts-income-by-a-third-in-low-income-communities-finds-landmark-new-study/2482212/A pair of reading glasses increases the earnings of people in low-income communities by 33%, according to new research. A new randomized controlled trial finds that the provision of reading glasses improves livelihoods and quality of life and reduces poverty. VisionSpring, BRAC, an